As of August 2026 — Disclosed Capitol has tracked 330 disclosed congressional trades in Bristol-Myers Squibb Company (BMY) — 163:152 sell-heavy ratio — led by Ro Khanna (D).

Which members of Congress trade Bristol-Myers Squibb Company?

• Ro Khanna (D) — 52 disclosed trades in BMY
• Michael McCaul (R) — 8 disclosed trades in BMY
• Thomas H Tuberville (R) — 7 disclosed trades in BMY
• Daniel Goldman (D) — 7 disclosed trades in BMY
• Julie Johnson (D) — 5 disclosed trades in BMY

Recent BMY congressional trades

Buy vs. sell ratio & volume

Across the 330 disclosed congressional trades in Bristol-Myers Squibb Company (BMY), members of Congress have reported 152 buys and 163 sells. The average 30-day alpha vs. the S&P 500 is -0.52%.

Does Bristol-Myers Squibb Company receive U.S. government contracts?

As of October 2026, Bristol-Myers Squibb Company has 91 federal contract award records on file from USAspending.gov — most recently $1.0M from the Department of Veterans Affairs on 2026-10-01.

Negative amounts are contract de-obligations. Browse and filter every award on the government contracts page.

Bristol-Myers Squibb Company financial snapshot (FY2025)

For fiscal year 2025, Bristol-Myers Squibb Company reported revenue of $48.30B and net income of -$8.95B, per SEC filings.

Revenue

$48.30B

Net income

-$8.95B

Diluted EPS

$-4.41

Net margin

-18.5%

Free cash flow

$13.94B

Most recent reported quarter: Q2 FY2026 — revenue $12.97B, net income $3.32B.

Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.